In this context, using a systematic review and meta‐analysis of randomized controlled trials (RCTs), we aimed to evaluate whether the combination of SGLT2 and RAAS inhibitors has a superior efficacy and safety profile than SGLT2‐Is alone in patients with type 2 diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.